NCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
34 trialsNCT05061420 2025-09-22
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Sanofi
Phase 2 Terminated
NCT05930938 2025-05-09
XXL_2022-01
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Terminated
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03254927 2023-04-03
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Celldex Therapeutics
Phase 2 Terminated
NCT02438995 2021-11-03
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Northwell Health
Phase 1 Terminated
NCT02817113 2021-04-30
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
Orient Europharma Co., Ltd.
Phase 1 Terminated
NCT02177838 2021-04-21
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Rutgers, The State University of New Jersey
Phase NA Terminated
NCT02822482 2021-03-29
COPAN-ORL06
UNICANCER
Phase 1/2 Terminated
NCT03887442 2021-01-07
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Terminated
NCT01326923 2020-10-09
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 2 Terminated
NCT02015650 2020-05-18
Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Medical University Innsbruck
Phase 4 Terminated
NCT01133678 2020-05-08
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
University of Chicago
Phase 2 Terminated
NCT02124850 2019-10-25
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Celgene
Phase 1 Terminated
NCT01871311 2019-02-08
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Georgetown University
Phase 1 Terminated
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT00882583 2019-01-09
Dasatinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated
NCT01009346 2018-07-17
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT00646659 2018-07-09
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01216020 2018-01-17
CTXMAB+RT
Azienda USL 4 Prato
Phase 2 Terminated
NCT00319839 2018-01-12
Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab
University of California, Irvine
Phase 2 Terminated
NCT01488318 2018-01-05
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
University of Pittsburgh
Phase 2 Terminated
NCT01221753 2017-12-06
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00570674 2017-11-13
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT01794845 2017-05-11
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
University of Miami
Phase 2 Terminated
NCT00927147 2017-01-31
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
Boneca Corporation
Phase 1/2 Terminated
NCT00599131 2015-12-03
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01790516 2014-10-02
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
Georgetown University
Phase NA Terminated
NCT01360827 2014-06-17
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated
NCT00004227 2014-02-06
Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
University of Alabama at Birmingham
Phase 3 Terminated
NCT00906360 2013-07-02
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01015664 2012-12-17
Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Tennessee Cancer Institute
Phase 1/2 Terminated